Literature DB >> 30967643

Biotherapeutics and immunogenicity: ophthalmic perspective.

Ashish Sharma1, Nilesh Kumar2, Baruch D Kuppermann3, Francesco Bandello4, Anat Loewenstein5.   

Abstract

Mesh：

Substances：

Year:  2019        PMID： 30967643      PMCID： PMC7002711          DOI： 10.1038/s41433-019-0434-y

Source DB:  PubMed          Journal:  Eye (Lond)        ISSN： 0950-222X            Impact factor:   3.775


× No keyword cloud information.
  15 in total

Review 1.  Comparative immunogenicity assessment of biosimilars.

Authors:  Thomas Schreitmüller; Bettina Barton; Artem Zharkov; Georgios Bakalos
Journal:  Future Oncol       Date:  2018-10-03       Impact factor: 3.404

2.  Estimated cases of legal blindness and visual impairment avoided using ranibizumab for choroidal neovascularization: non-Hispanic white population in the United States with age-related macular degeneration.

Authors:  Neil M Bressler; Quan V Doan; Rohit Varma; Paul P Lee; Ivan J Suñer; Chantal Dolan; Mark D Danese; Elaine Yu; Irwin Tran; Shoshana Colman
Journal:  Arch Ophthalmol       Date:  2011-06

Review 3.  Approaching the asymptote? Evolution and revolution in immunology.

Authors:  C A Janeway
Journal:  Cold Spring Harb Symp Quant Biol       Date:  1989

4.  Immunogenicity testing of therapeutic antibodies in ocular fluids after intravitreal injection.

Authors:  Uwe Wessels; Markus Zadak; Astrid Reiser; Janis Brockhaus; Mirko Ritter; Afsaneh Abdolzade-Bavil; Julia Heinrich; Kay Stubenrauch
Journal:  Bioanalysis       Date:  2018-04-11       Impact factor: 2.681

Review 5.  Immunogenicity of engineered antibodies.

Authors:  William Ying Khee Hwang; Jefferson Foote
Journal:  Methods       Date:  2005-05       Impact factor: 3.608

Review 6.  Immunology of age-related macular degeneration.

Authors:  Jayakrishna Ambati; John P Atkinson; Bradley D Gelfand
Journal:  Nat Rev Immunol       Date:  2013-06       Impact factor: 53.106

7.  Severe Ocular Inflammation Following Ranibizumab or Aflibercept Injections for Age-Related Macular Degeneration: A Retrospective Claims Database Analysis.

Authors:  Eric H Souied; Pravin U Dugel; Alberto Ferreira; Ron Hashmonay; Jingsong Lu; Simon P Kelly
Journal:  Ophthalmic Epidemiol       Date:  2016-02-08       Impact factor: 1.648

8.  Anti-VEGF drugs in the prevention of blindness.

Authors:  David Yorston
Journal:  Community Eye Health       Date:  2014

Review 9.  Vitreous inflammation associated with intravitreal anti-VEGF pharmacotherapy.

Authors:  Shivi Agrawal; Malav Joshi; John B Christoforidis
Journal:  Mediators Inflamm       Date:  2013-11-06       Impact factor: 4.711

Review 10.  Potential Sources and Roles of Adaptive Immunity in Age-Related Macular Degeneration: Shall We Rename AMD into Autoimmune Macular Disease?

Authors:  Serge Camelo
Journal:  Autoimmune Dis       Date:  2014-04-30
View more
  4 in total

1.  Ophthalmic biosimilars: Lessons from India.

Authors:  Ashish Sharma; Nilesh Kumar; Baruch D Kuppermann; Bandello Francesco; Anat Lowenstein
Journal:  Indian J Ophthalmol       Date:  2019-08       Impact factor: 1.848

2.  Fear of safety compromise with biosimilar anti-VEGF-perception or truth.

Authors:  Ashish Sharma; Nikulaa Parachuri; Nilesh Kumar; Francesco Bandello; Baruch D Kuppermann
Journal:  Eye (Lond)       Date:  2022-05-26       Impact factor: 4.456

Review 3.  Future of anti-VEGF: biosimilars and biobetters.

Authors:  Monika Kapur; Suvansh Nirula; Mayuresh P Naik
Journal:  Int J Retina Vitreous       Date:  2022-01-04

4.  Ranizurel safety evaluation in real-world -(RaSER) study.

Authors:  Ashish Sharma; Jayshree Arunaprakash; Atheeshwar Das; Ashraya Nayaka; Nilesh Kumar; Nikulaa Parachuri; Baruch D Kuppermann
Journal:  Am J Ophthalmol Case Rep       Date:  2022-02-02
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.